Published in Proc Natl Acad Sci U S A on August 01, 1982
Eukaryotic transient-expression system based on recombinant vaccinia virus that synthesizes bacteriophage T7 RNA polymerase. Proc Natl Acad Sci U S A (1986) 32.58
Vaccinia virus expression vector: coexpression of beta-galactosidase provides visual screening of recombinant virus plaques. Mol Cell Biol (1985) 13.99
General method for production and selection of infectious vaccinia virus recombinants expressing foreign genes. J Virol (1984) 10.98
Construction and characterization of an infectious vaccinia virus recombinant that expresses the influenza hemagglutinin gene and induces resistance to influenza virus infection in hamsters. Proc Natl Acad Sci U S A (1983) 4.69
Foot-and-mouth disease. Clin Microbiol Rev (2004) 4.34
Eukaryotic transient expression system dependent on transcription factors and regulatory DNA sequences of vaccinia virus. Proc Natl Acad Sci U S A (1985) 3.61
Construction of live vaccines using genetically engineered poxviruses: biological activity of vaccinia virus recombinants expressing the hepatitis B virus surface antigen and the herpes simplex virus glycoprotein D. Proc Natl Acad Sci U S A (1984) 3.58
Resistance to human respiratory syncytial virus (RSV) infection induced by immunization of cotton rats with a recombinant vaccinia virus expressing the RSV G glycoprotein. Proc Natl Acad Sci U S A (1986) 3.53
Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc Natl Acad Sci U S A (1996) 3.29
One hundred base pairs of 5' flanking sequence of a vaccinia virus late gene are sufficient to temporally regulate late transcription. Proc Natl Acad Sci U S A (1985) 3.23
Isolation and characterization of neutralizing monoclonal antibodies to vaccinia virus. J Virol (1985) 3.06
Transient dominant selection of recombinant vaccinia viruses. J Virol (1990) 2.97
Construction of live vaccines by using genetically engineered poxviruses: biological activity of recombinant vaccinia virus expressing influenza virus hemagglutinin. Proc Natl Acad Sci U S A (1983) 2.79
A 14,000-Mr envelope protein of vaccinia virus is involved in cell fusion and forms covalently linked trimers. J Virol (1987) 2.53
Negative-strand RNA viruses: genetic engineering and applications. Proc Natl Acad Sci U S A (1996) 2.47
Conserved TAAAT motif in vaccinia virus late promoters: overlapping TATA box and site of transcription initiation. EMBO J (1986) 2.41
A human parvovirus, adeno-associated virus, as a eucaryotic vector: transient expression and encapsidation of the procaryotic gene for chloramphenicol acetyltransferase. Mol Cell Biol (1984) 2.36
Adeno-associated virus vector for high-frequency integration, expression, and rescue of genes in mammalian cells. Mol Cell Biol (1985) 2.21
Applications of pox virus vectors to vaccination: an update. Proc Natl Acad Sci U S A (1996) 2.10
Nucleotide sequence of a cluster of early and late genes in a conserved segment of the vaccinia virus genome. Nucleic Acids Res (1985) 2.02
Expression of the major glycoprotein G of human respiratory syncytial virus from recombinant vaccinia virus vectors. Proc Natl Acad Sci U S A (1986) 1.85
Cloning and expression of foreign genes in vaccinia virus, using a host range selection system. J Virol (1989) 1.84
Expression of Sindbis virus structural proteins via recombinant vaccinia virus: synthesis, processing, and incorporation into mature Sindbis virions. J Virol (1985) 1.75
A poxvirus-derived vector that directs high levels of expression of cloned genes in mammalian cells. Proc Natl Acad Sci U S A (1988) 1.72
Sequence-nonspecific replication of transfected plasmid DNA in poxvirus-infected cells. Proc Natl Acad Sci U S A (1986) 1.71
Cryo-electron tomography of vaccinia virus. Proc Natl Acad Sci U S A (2005) 1.48
Host range restricted, non-replicating vaccinia virus vectors as vaccine candidates. Adv Exp Med Biol (1996) 1.44
Protection of mice from fatal measles encephalitis by vaccination with vaccinia virus recombinants encoding either the hemagglutinin or the fusion protein. Proc Natl Acad Sci U S A (1988) 1.43
Generation of a dominant 8-MDa deletion at the left terminus of vaccinia virus DNA. Proc Natl Acad Sci U S A (1985) 1.41
Delineation of the viral products of recombination in vaccinia virus-infected cells. J Virol (1988) 1.40
High-frequency homologous recombination in vaccinia virus DNA. J Virol (1987) 1.39
Protection against anthrax with recombinant virus-expressed protective antigen in experimental animals. Infect Immun (1991) 1.37
Cis-acting sequences affecting the length of the poly(A) head of vaccinia virus late transcripts. Nucleic Acids Res (1988) 1.35
Molecular attenuation of vaccinia virus: mutant generation and animal characterization. J Virol (1992) 1.34
Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a murine tumor model. Vaccine (1997) 1.32
Anchoring a secreted plasmodium antigen on the surface of recombinant vaccinia virus-infected cells increases its immunogenicity. Mol Cell Biol (1986) 1.31
Effect of the recombinant vaccinia viruses that express HTLV-I envelope gene on HTLV-I infection. EMBO J (1987) 1.27
Rationalizing the development of live attenuated virus vaccines. Nat Biotechnol (2010) 1.26
Mutational analysis of a vaccinia virus intermediate promoter in vivo and in vitro. J Virol (1990) 1.25
M protein (M1) of influenza virus: antigenic analysis and intracellular localization with monoclonal antibodies. J Virol (1989) 1.24
Effects and virulences of recombinant vaccinia viruses derived from attenuated strains that express the human T-cell leukemia virus type I envelope gene. J Virol (1988) 1.23
Reverse genetics of negative-strand RNA viruses: closing the circle. Proc Natl Acad Sci U S A (1999) 1.23
A tandemly-oriented late gene cluster within the vaccinia virus genome. Nucleic Acids Res (1986) 1.20
Generation of hybrid genes and proteins by vaccinia virus-mediated recombination: application to human immunodeficiency virus type 1 env. J Virol (1990) 1.19
Establishment of a foreign antigen secretion system in mycobacteria. Infect Immun (1990) 1.18
Immune response in skunks to a vaccinia virus recombinant expressing the rabies virus glycoprotein. Can J Vet Res (1987) 1.16
Varicella-zoster virus as a live vector for the expression of foreign genes. Proc Natl Acad Sci U S A (1987) 1.15
Highly attenuated vaccinia virus mutants for the generation of safe recombinant viruses. Proc Natl Acad Sci U S A (1989) 1.14
Structural and functional studies of a 39,000-Mr immunodominant protein of vaccinia virus. J Virol (1987) 1.12
Mapping of the genes coding for the two major vaccinia virus core polypeptides. Nucleic Acids Res (1984) 1.12
Newcastle disease virus fusion protein expressed in a fowlpox virus recombinant confers protection in chickens. J Virol (1990) 1.11
Insertional inactivation of the vaccinia virus 32-kilodalton gene is associated with attenuation in mice and reduction of viral gene expression in polarized epithelial cells. J Virol (1992) 1.10
Identification and nucleotide sequence of the thymidine kinase gene of Shope fibroma virus. J Virol (1986) 1.09
BK virus-plasmid expression vector that persists episomally in human cells and shuttles into Escherichia coli. Mol Cell Biol (1984) 1.06
Vaccinia virus recombinants expressing the SA11 rotavirus VP7 glycoprotein gene induce serotype-specific neutralizing antibodies. J Virol (1987) 1.05
The African swine fever virus thymidine kinase gene is required for efficient replication in swine macrophages and for virulence in swine. J Virol (1998) 1.03
The evolution of poxvirus vaccines. Viruses (2015) 1.02
Plaque size phenotype as a selectable marker to generate vaccinia virus recombinants. J Virol (1989) 1.00
Synthesis of bovine growth hormone in primates by using a herpesvirus vector. Mol Cell Biol (1985) 1.00
Expression of the Bacillus anthracis protective antigen gene by baculovirus and vaccinia virus recombinants. Infect Immun (1990) 1.00
Synthesis, cellular location, and immunogenicity of bovine herpesvirus 1 glycoproteins gI and gIII expressed by recombinant vaccinia virus. J Virol (1989) 1.00
Poxvirus vectors as HIV/AIDS vaccines in humans. Hum Vaccin Immunother (2012) 1.00
Effective tumor immunotherapy directed against an oncogene-encoded product using a vaccinia virus vector. Proc Natl Acad Sci U S A (1987) 0.99
Recombinant vaccinia virus vaccine against the human melanoma antigen p97 for use in immunotherapy. Proc Natl Acad Sci U S A (1988) 0.99
Expression in recombinant vaccinia virus of the equine herpesvirus 1 gene encoding glycoprotein gp13 and protection of immunized animals. J Virol (1989) 0.99
Vaccinia viruses: vaccines against smallpox and vectors against infectious diseases and tumors. Expert Rev Vaccines (2011) 0.98
Immune responses to H-2Kd antigen expressed by recombinant vaccinia virus. Proc Natl Acad Sci U S A (1986) 0.97
Transduction of the Chinese hamster ovary aprt gene by herpes simplex virus. J Virol (1984) 0.96
Developments in Viral Vector-Based Vaccines. Vaccines (Basel) (2014) 0.94
Protection against myxomatosis and rabbit viral hemorrhagic disease with recombinant myxoma viruses expressing rabbit hemorrhagic disease virus capsid protein. J Virol (1996) 0.93
Response of dairy calves to vaccinia viruses that express foreign genes. J Clin Microbiol (1986) 0.93
Non-replicating expression vectors: applications in vaccine development and gene therapy. Epidemiol Infect (1996) 0.92
Vaccinia virus protein N2 is a nuclear IRF3 inhibitor that promotes virulence. J Gen Virol (2013) 0.90
Identification of the thymidine kinase gene of feline herpesvirus: use of degenerate oligonucleotides in the polymerase chain reaction to isolate herpesvirus gene homologs. J Virol (1989) 0.90
RNA virus vectors: where are we and where do we need to go? Proc Natl Acad Sci U S A (1998) 0.90
Construction of chimeric vaccinia viruses by molecular cloning and packaging. Proc Natl Acad Sci U S A (1992) 0.89
The immunogenicity of VP7, a rotavirus antigen resident in the endoplasmic reticulum, is enhanced by cell surface expression. J Virol (1990) 0.89
Construction of fowlpox virus vectors with intergenic insertions: expression of the beta-galactosidase gene and the measles virus fusion gene. J Virol (1990) 0.89
Enzymatic processing of replication and recombination intermediates by the vaccinia virus DNA polymerase. Nucleic Acids Res (2005) 0.88
A mechanism for the inhibition of DNA-PK-mediated DNA sensing by a virus. PLoS Pathog (2013) 0.88
A recombinant vaccinia virus encoding inducible nitric oxide synthase is attenuated in vivo. J Virol (1996) 0.88
Reflections on the early development of poxvirus vectors. Vaccine (2013) 0.88
Vaccinia virus protein K7 is a virulence factor that alters the acute immune response to infection. J Gen Virol (2013) 0.86
Virus-vectored influenza virus vaccines. Viruses (2014) 0.86
Deletion of immunomodulator C6 from vaccinia virus strain Western Reserve enhances virus immunogenicity and vaccine efficacy. J Gen Virol (2013) 0.86
Enhancing poxvirus vectors vaccine immunogenicity. Hum Vaccin Immunother (2014) 0.85
Construction and characterization of a triple-recombinant vaccinia virus encoding B7-1, interleukin 12, and a model tumor antigen. J Natl Cancer Inst (1998) 0.85
Genome scale patterns of recombination between coinfecting vaccinia viruses. J Virol (2014) 0.85
New aspects of vaccine development. Clin Exp Immunol (1985) 0.83
Isolation of cis-acting vaccinia virus DNA fragments promoting the expression of herpes simplex virus thymidine kinase by recombinant viruses. J Virol (1985) 0.83
OX40:OX40L axis: emerging targets for improving poxvirus-based CD8(+) T-cell vaccines against respiratory viruses. Immunol Rev (2011) 0.82
Viral vector-based influenza vaccines. Hum Vaccin Immunother (2016) 0.79
Utilization of DNA recombination for the two-step replacement of growth factor sequences in the vaccinia virus genome. J Virol (1991) 0.76
Selection of recombinant MVA by rescue of the essential D4R gene. Virol J (2011) 0.76
Vaccinia virus recombinants expressing an 11-kilodalton beta-galactosidase fusion protein incorporate active beta-galactosidase in virus particles. J Virol (1988) 0.75
Human poxvirus infection after the eradication of smallpox. Epidemiol Infect (1988) 0.75
Investigating Viruses during the Transformation of Molecular Biology. J Biol Chem (2017) 0.75
Detection of specific sequences among DNA fragments separated by gel electrophoresis. J Mol Biol (1975) 503.08
Labeling deoxyribonucleic acid to high specific activity in vitro by nick translation with DNA polymerase I. J Mol Biol (1977) 205.11
A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology (1973) 127.36
Construction and characterization of new cloning vehicles. II. A multipurpose cloning system. Gene (1977) 114.87
Efficient transfer of large DNA fragments from agarose gels to diazobenzyloxymethyl-paper and rapid hybridization by using dextran sulfate. Proc Natl Acad Sci U S A (1979) 72.18
Supercoiled circular DNA-protein complex in Escherichia coli: purification and induced conversion to an opern circular DNA form. Proc Natl Acad Sci U S A (1969) 71.62
A complementation analysis of the restriction and modification of DNA in Escherichia coli. J Mol Biol (1969) 71.21
A rapid boiling method for the preparation of bacterial plasmids. Anal Biochem (1981) 59.01
Nature of Col E 1 plasmid replication in Escherichia coli in the presence of the chloramphenicol. J Bacteriol (1972) 46.61
Preparative and analytical purification of DNA from agarose. Proc Natl Acad Sci U S A (1979) 27.20
Prolonged incubation in calcium chloride improves the competence of Escherichia coli cells. Gene (1979) 25.53
Transfer of purified herpes virus thymidine kinase gene to cultured mouse cells. Cell (1977) 18.95
Plasmid screening at high colony density. Gene (1980) 16.47
Nucleotide sequence of the thymidine kinase gene of herpes simplex virus type 1. Proc Natl Acad Sci U S A (1981) 10.04
Synthesis of rabbit beta-globin in cultured monkey kidney cells following infection with a SV40 beta-globin recombinant genome. Nature (1979) 9.99
The nucleotide sequence and transcript map of the herpes simplex virus thymidine kinase gene. Nucleic Acids Res (1980) 9.96
The purification fo four strains of poxvirus. Virology (1962) 8.55
Hybridization in situ of SV40 plaques: detection of recombinant SV40 virus carrying specific sequences of nonviral DNA. Science (1977) 5.75
Expression of the mouse dihydrofolate reductase complementary deoxyribonucleic acid in simian virus 40 vectors. Mol Cell Biol (1981) 5.00
Bovine papilloma virus deoxyribonucleic acid: a novel eucaryotic cloning vector. Mol Cell Biol (1981) 4.75
Rabbit beta-globin mRNA production in mouse L cells transformed with cloned rabbit beta-globin chromosomal DNA. Nature (1979) 3.88
Formation of infectious progeny virus after insertion of herpes simplex thymidine kinase gene into DNA of an avian retrovirus. Cell (1981) 3.80
Introduction and expression of a rabbit beta-globin gene in mouse fibroblasts. Proc Natl Acad Sci U S A (1979) 3.53
Expression of the hepatitis B virus surface antigen gene in cell culture by using a simian virus 40 vector. Proc Natl Acad Sci U S A (1981) 3.38
Cell-surface expression of influenza haemagglutinin from a cloned DNA copy of the RNA gene. Nature (1981) 3.29
Molecular genetics of vaccinia virus: demonstration of marker rescue. Proc Natl Acad Sci U S A (1982) 3.01
Expression of simian virus 40-rat preproinsulin recombinants in monkey kidney cells: use of preproinsulin RNA processing signals. Proc Natl Acad Sci U S A (1981) 2.76
Two major DNA variants present in serially propagated stocks of the WR strain of vaccinia virus. J Virol (1981) 2.74
Expression of the chromosomal mouse Beta maj-globin gene cloned in SV40. Nature (1979) 2.29
The preparation of orthopoxvirus DNA. J Virol Methods (1981) 2.28
Virus type-specific thymidine kinase in cells biochemically transformed by herpes simplex virus types 1 and 2. J Virol (1974) 2.16
Mapping of early SV40-specific functions by microinjection of different early viral DNA fragments. Cell (1978) 2.08
Selective assay for herpes simplex viruses expressing thymidine kinase. J Virol (1979) 2.03
Phosphorylation of 5-bromodeoxycytidine in cells infected with herpes simplex virus. Proc Natl Acad Sci U S A (1973) 2.02
Functional expression in primate cells of cloned DNA coding for the hemagglutinin surface glycoprotein of influenza virus. Proc Natl Acad Sci U S A (1981) 1.75
Translation of rabbit globin mRNA introduced by liposomes into mouse lymphocytes. Nature (1978) 1.54
SV40 recombinant molecules express the gene encoding p21 transforming protein of Harvey murine sarcoma virus. Nature (1981) 1.39
Evidence for translation of rabbit globin mRNA after liposome-mediated insertion into a human cell line. Nature (1978) 1.31
Red cell-mediated microinjection. Natl Cancer Inst Monogr (1978) 1.11
Analysis of vaccinia virus transcriptional complexity in vitro and in vivo: characterization of RNase T1-resistant 5'-terminal oligonucleotides. J Virol (1982) 0.93
The complete DNA sequence of vaccinia virus. Virology (1990) 7.76
RNA polymerase activity in purified infectious vaccinia virus. Proc Natl Acad Sci U S A (1967) 5.49
Purification of mRNA guanylyltransferase and mRNA (guanine-7-) methyltransferase from vaccinia virions. J Biol Chem (1975) 3.66
Construction of live vaccines using genetically engineered poxviruses: biological activity of vaccinia virus recombinants expressing the hepatitis B virus surface antigen and the herpes simplex virus glycoprotein D. Proc Natl Acad Sci U S A (1984) 3.58
Electrophoresis of thymidine kinase activity synthesized by cells transformed by herpes simplex virus. Virology (1972) 3.05
Molecular genetics of vaccinia virus: demonstration of marker rescue. Proc Natl Acad Sci U S A (1982) 3.01
Construction of live vaccines by using genetically engineered poxviruses: biological activity of recombinant vaccinia virus expressing influenza virus hemagglutinin. Proc Natl Acad Sci U S A (1983) 2.79
Two major DNA variants present in serially propagated stocks of the WR strain of vaccinia virus. J Virol (1981) 2.74
Vaccinia virus-encoded eIF-2 alpha homolog abrogates the antiviral effect of interferon. Virology (1991) 2.63
Reversal of the interferon-sensitive phenotype of a vaccinia virus lacking E3L by expression of the reovirus S4 gene. J Virol (1995) 2.55
Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen. J Immunol (1995) 2.45
Detection of major histocompatibility complex class I-restricted, HIV-specific cytotoxic T lymphocytes in the blood of infected hemophiliacs. Blood (1989) 2.37
Nucleotide phosphohydrolase in purified vaccinia virus. J Virol (1968) 2.35
A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin Cancer Res (2000) 2.28
Protein kinase and specific phosphate acceptor proteins associated with vaccinia virus cores. J Virol (1972) 2.22
Japanese encephalitis virus-vaccinia recombinants produce particulate forms of the structural membrane proteins and induce high levels of protection against lethal JEV infection. Virology (1991) 2.17
Mice immunized with a subviral particle containing the Japanese encephalitis virus prM/M and E proteins are protected from lethal JEV infection. Virology (1992) 2.15
Applications of pox virus vectors to vaccination: an update. Proc Natl Acad Sci U S A (1996) 2.10
Modification of the 5'-terminus of mRNA by soluble guanylyl and methyl transferases from vaccinia virus. Proc Natl Acad Sci U S A (1975) 2.10
Immunisation with canarypox virus expressing rabies glycoprotein. Lancet (1992) 2.09
Vaccinia virus host range genes. Virology (1990) 2.02
HIV-1 recombinant poxvirus vaccine induces cross-protection against HIV-2 challenge in rhesus macaques. Nat Med (1995) 1.99
Recombinant vaccine-induced protection against the highly pathogenic simian immunodeficiency virus SIV(mac251): dependence on route of challenge exposure. J Virol (1998) 1.98
An update on the vaccinia virus genome. Virology (1993) 1.95
Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer. Urology (1999) 1.92
Antigenic specificity of antibody-dependent cell-mediated cytotoxicity directed against human immunodeficiency virus in antibody-positive sera. J Virol (1989) 1.87
Cloning and expression of foreign genes in vaccinia virus, using a host range selection system. J Virol (1989) 1.84
TAR RNA-binding protein is an inhibitor of the interferon-induced protein kinase PKR. Proc Natl Acad Sci U S A (1994) 1.80
Polyadenylate polymerase from vaccinia virions. Nat New Biol (1973) 1.76
Two nucleic acid-dependent nucleoside triphosphate phosphohydrolases from vaccinia virus. Nucleotide substrate and polynucleotide cofactor specificities. J Biol Chem (1974) 1.76
Recombinant vaccinia virus producing the prM and E proteins of yellow fever virus protects mice from lethal yellow fever encephalitis. Virology (1992) 1.76
Efficacy of nucleoprotein and haemagglutinin antigens expressed in fowlpox virus as vaccine for influenza in chickens. Vaccine (1991) 1.66
Vaccinia virus vectors utilizing the beta-galactosidase assay for rapid selection of recombinant viruses and measurement of gene expression. Gene (1986) 1.64
Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group. J Infect Dis (1998) 1.64
Recombinant vaccinia virus: immunization against multiple pathogens. Science (1985) 1.60
Recombinant fowlpox virus inducing protective immunity in non-avian species. Vaccine (1988) 1.55
Comparison of protective immunity elicited by recombinant vaccinia viruses that synthesize E or NS1 of Japanese encephalitis virus. Virology (1991) 1.55
Host-range restriction of vaccinia virus E3L-specific deletion mutants. Virus Genes (1996) 1.53
Transcriptional complexity of vaccinia virus in vivo and in vitro. J Virol (1977) 1.53
Antibody-dependent cell-mediated cytotoxicity directed by a human monoclonal antibody reactive with gp120 of HIV-1. AIDS (1991) 1.53
Effect of canarypox virus (ALVAC)-mediated cytokine expression on murine prostate tumor growth. J Natl Cancer Inst (1997) 1.52
Normal immune function and inability to isolate virus in culture in an individual with long-term human immunodeficiency virus type 1 infection. AIDS Res Hum Retroviruses (1994) 1.51
Nonreplicating viral vectors as potential vaccines: recombinant canarypox virus expressing measles virus fusion (F) and hemagglutinin (HA) glycoproteins. Virology (1992) 1.48
High molecular weight virion-associated RNA of vaccinia. A possible precursor to 8 to 12 S mRNA. J Biol Chem (1977) 1.45
Recombinant vaccinia viruses co-expressing dengue-1 glycoproteins prM and E induce neutralizing antibodies in mice. Vaccine (1994) 1.43
Role of the vaccinia virus E3L and K3L gene products in rescue of VSV and EMCV from the effects of IFN-alpha. J Interferon Cytokine Res (1998) 1.38
Distinct patterns of IFN sensitivity observed in cells infected with vaccinia K3L- and E3L- mutant viruses. Virology (1995) 1.36
Vaccinia virus rifampicin-resistance locus specifies a late 63,000 Da gene product. Virology (1986) 1.35
Protective immunity against avian influenza induced by a fowlpox virus recombinant. Vaccine (1988) 1.35
Deletion of 55 open reading frames from the termini of vaccinia virus. Virology (1991) 1.34
Fowlpox virus as a vector in non-avian species. Vaccine (1988) 1.29
Recombinant vaccinia virus expression of the bovine leukaemia virus envelope gene and protection of immunized sheep against infection. Vaccine (1991) 1.28
Poxvirus-based vaccine candidates for cancer, AIDS, and other infectious diseases. J Leukoc Biol (1995) 1.27
Induction of human immunodeficiency virus type 1 (HIV-1)-specific cytolytic T lymphocyte responses in seronegative adults by a nonreplicating, host-range-restricted canarypox vector (ALVAC) carrying the HIV-1MN env gene. J Infect Dis (1995) 1.26
Vaccinia virus as an expression vector. Methods Enzymol (1987) 1.25
Potential use of non-replicating vectors as recombinant vaccines. Vaccine (1992) 1.25
Vaccinia virus recombinants expressing either the measles virus fusion or hemagglutinin glycoprotein protect dogs against canine distemper virus challenge. J Virol (1991) 1.24
M protein (M1) of influenza virus: antigenic analysis and intracellular localization with monoclonal antibodies. J Virol (1989) 1.24
A highly attenuated host range-restricted vaccinia virus strain, NYVAC, encoding the prM, E, and NS1 genes of Japanese encephalitis virus prevents JEV viremia in swine. Virology (1992) 1.24
Molecular complexity of vaccinia DNA and the presence of reiterated sequences in the genome. Virology (1977) 1.23
Physical mapping and DNA sequence analysis of the rifampicin resistance locus in vaccinia virus. Virology (1985) 1.22
NYVAC-Pf7: a poxvirus-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. Infect Immun (1996) 1.20
Efficacy studies on a canarypox-rabies recombinant virus. Vaccine (1991) 1.20
Generation of hybrid genes and proteins by vaccinia virus-mediated recombination: application to human immunodeficiency virus type 1 env. J Virol (1990) 1.19
Vaccinia: virus, vector, vaccine. Adv Virus Res (1988) 1.19
Early HIV-1 envelope-specific cytotoxic T lymphocyte responses in vertically infected infants. J Exp Med (1997) 1.19
In vitro synthesis of a high molecular weight virion-associated RNA by vaccinia. J Biol Chem (1977) 1.17
Multiple immunizations with attenuated poxvirus HIV type 2 recombinants and subunit boosts required for protection of rhesus macaques. AIDS Res Hum Retroviruses (1996) 1.16
Fusogenic segments of bovine leukemia virus and simian immunodeficiency virus are interchangeable and mediate fusion by means of oblique insertion in the lipid bilayer of their target cells. Proc Natl Acad Sci U S A (1992) 1.16
Biological and immunogenic properties of a canarypox-rabies recombinant, ALVAC-RG (vCP65) in non-avian species. Vaccine (1995) 1.15
Single-stranded deoxyribonucleic acid-specific nuclease from vaccinia virus. Purification and characterization. J Biol Chem (1974) 1.14
Immunogenicity and protective efficacy of a human immunodeficiency virus type 2 recombinant canarypox (ALVAC) vaccine candidate in cynomolgus monkeys. J Infect Dis (1996) 1.13
p53 as a target for cancer vaccines: recombinant canarypox virus vectors expressing p53 protect mice against lethal tumor cell challenge. Proc Natl Acad Sci U S A (1996) 1.11
Newcastle disease virus fusion protein expressed in a fowlpox virus recombinant confers protection in chickens. J Virol (1990) 1.11
Effects of subcutaneous calcitriol administration on plasma calcium and parathyroid hormone concentrations in continuous ambulatory peritoneal dialysis uremic patients. Perit Dial Int (1993) 1.07
Equine herpesvirus type 1 unique short fragment encodes glycoproteins with homology to herpes simplex virus type 1 gD, gI and gE. J Gen Virol (1990) 1.07
Mutations in ORF D13L and other genetic loci alter the rifampicin phenotype of vaccinia virus. Virology (1993) 1.06
Poxvirus-based vectors as vaccine candidates. Crit Rev Immunol (1990) 1.05
A DNA ligase gene in the Copenhagen strain of vaccinia virus is nonessential for viral replication and recombination. Virology (1990) 1.05
Comparison of numerous delivery systems for the induction of cytotoxic T lymphocytes by immunization. Eur J Immunol (1996) 1.04
Deoxyribonucleic acid-dependent nucleotide phosphohydrolase activity in purified vaccinia virus. J Virol (1972) 1.04
Methyl group analysis of virion-associated high-molecular-weight RNA synthesized in vitro by purified vaccinia virus. J Virol (1977) 1.04
Attenuated vaccinia virus-circumsporozoite protein recombinants confer protection against rodent malaria. Infect Immun (1996) 1.03
The role of ATP in the biogenesis of vaccinia virus mRNA in vitro. Virology (1978) 1.03
Insertion and deletion mutants of vaccinia virus. Virology (1986) 1.02
Regulation of synthesis of two immunologically distinct nucleic acid-dependent nucleoside triphosphate phosphohydrolases in vaccinia virus-infected HeLa cells. J Virol (1974) 1.02
Protection of cats against feline leukemia virus by vaccination with a canarypox virus recombinant, ALVAC-FL. J Virol (1993) 1.01
The safety and use of canarypox vectored vaccines. Dev Biol Stand (1995) 0.99
Protection of mice and swine from pseudorabies virus conferred by vaccinia virus-based recombinants. J Virol (1992) 0.99
Effective tumor immunotherapy directed against an oncogene-encoded product using a vaccinia virus vector. Proc Natl Acad Sci U S A (1987) 0.99
Expression in recombinant vaccinia virus of the equine herpesvirus 1 gene encoding glycoprotein gp13 and protection of immunized animals. J Virol (1989) 0.99
Memory cytotoxic T lymphocyte responses in human immunodeficiency virus type 1 (HIV-1)-negative volunteers immunized with a recombinant canarypox expressing gp 160 of HIV-1 and boosted with a recombinant gp160. J Infect Dis (1996) 0.98